Jump to content
Retatrutide Script

sources

Retatrutide References and Study Links

Each numbered source appears here. Its link opens the journal page, a short study summary, or the full paper.

Where can you read the full study list?

A study number isn't much help to you by itself. The full list is below. Each source gives the authors, study title, journal, and date. One web link may open the journal's page. Another may open a short summary or the full paper for free.

  1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. ↗
  2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. ↗
  3. Li W, Zhou Q, Cong Z, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. ↗
  4. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400:1869-1881. ↗
  5. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. ↗
  6. Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. ↗
  7. Madsbad S, et al. The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines. Expert Opinion on Investigational Drugs. 2025;34(3):197-215. ↗
  8. Melson E, et al. What is the pipeline for future medications for obesity? International Journal of Obesity. 2025;49(3):433-451. ↗
  9. Caruso I, et al. Incretin-based therapies for the treatment of obesity-related diseases. npj Metabolic Health and Disease. 2024;2(1):31. ↗
  10. Deravi M, et al. The "Weight" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity. Journal of Pharmacy Technology. 2024;40(6):300-305. ↗
  11. Cooper ME, et al. GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity. Journal of Clinical Investigation. 2025;135(21):e194749. ↗
  12. Takrori E, et al. Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review. Medicina (Kaunas). 2025. ↗
  13. Cho YK, et al. Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders. Clinical and Molecular Hepatology. 2026. ↗
  14. Muzurović E, et al. Emerging incretin- and multi-agonist-based treatments - the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond. Metabolism: Clinical and Experimental. 2026. ↗